Predictive value of plasma plasminogen activator inhibitor-1 for coronary restenosis: Dependence on stent implantation and antithrombotic medication

Journal of Thrombosis and Haemostasis

Volumn 3, Issue 2, 2005, Pages 233-239

  Christ, G ^a   Nikfardjam, M ^a   Huber Beckmann, R ^a   Gottsauner Wolf, M ^a   Glogar, D ^a   Binder, B R ^a   Wojta, J ^a   Huber, K ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Cardiology and Emergency Medicine   (Austria)

Author keywords

Coumadin; PAI 1; Restenosis; Ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; DIPYRIDAMOLE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN; FIBRINOLYTIC AGENT; PYRIDINE DERIVATIVE; THIENOPYRIDINE;

ADULT; AGED; ANGIOGRAPHY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; FEMALE; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RESTENOSIS; REVIEW; ARTICLE; BLOOD; FIBRINOLYSIS; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; STENT; TRANSLUMINAL CORONARY ANGIOPLASTY;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ASPIRIN; COMBINED MODALITY THERAPY; CORONARY RESTENOSIS; FEMALE; FIBRINOLYSIS; FIBRINOLYTIC AGENTS; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; PREDICTIVE VALUE OF TESTS; PYRIDINES; RETROSPECTIVE STUDIES; STENTS; TICLOPIDINE; TISSUE PLASMINOGEN ACTIVATOR;

EID: 20844434530     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2004.01062.x     Document Type: Review

References (28)

1. Serruys PW, Luijten HE, Beatt KJ, Geuskens R, de Feyter PJ, van den Brand M, Reiber JH, ten Katen HJ, van Es GA, Hugenholtz PG. Incidence of restenosis after successful coronary angioplasty: a time-related phenomenon. A quantitative angiographic study in 342 consecutive patients at 1, 2, 3, and 4 months. Circulation 1988; 77: 361-71.
2. Fischman DL, Leon MB, Bairn DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med 1994; 331: 496-501.
3. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. N Engl J Med 1994; 331: 489-95.
4. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985; 6: 369-75.
5. Nakatani M, Takeyama Y, Shibata M, Yorozuya M, Suzuki H, Koba S, Katagiri T. Mechanisms of restenosis after coronary intervention. Difference between plain old balloon angioplasty and stenting. Cardiovasc Pathol 2003; 12: 40-8.
6. Clowes AW, Clowes MM, Au YP, Reidy MA, Belin D. Smooth muscle cells express urokinase during mitogenesis and tissue- type plasminogen activator during migration in injured rat carotid artery. Circ Res 1990; 67: 61-7.
7. Reidy MA, Irvin C, Lindner V. Migration of arterial wall cells. Expression of plasminogen activators and inhibitors in injured rat arteries. Circ Res 1996; 78: 405-14.
8. Carmeliet P, Moons L, Lijnen R, Janssens S, Lupu F, Collen D, Gerard RD. Inhibitory role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: a gene targeting and gene transfer study in mice. Circulation 1997; 96: 3180-91.
9. Carmeliet P, Moons L, Herbert JM, Crawley J, Lupu F, Lijnen R, Collen D. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice. Circ Res 1997; 81: 829-39.
10. Christ G, Kostner K, Zehetgruber M, Binder BR, Gulba D, Huber K. Plasmin activation system in restenosis: role in pathogenesis and clinical prediction? J Thromb Thrombolysis 1999; 7: 277-85.
11. Prisco D, Fedi S, Antonucci E, Capanni M, Chiarugi L, Chioccioli M, Falai M, Giglioli C, Abbate R, Gensini GF. Postprocedural PAI-1 activity is a risk marker of subsequent clinical restenosis in patients both with and without stent implantation after elective balloon PTCA. Thromb Res 2001; 104: 181-6.
12. Sakata K, Miura F, Sugino H, Shinobe M, Shirotani M, Yoshida H, Mori N, Hoshino T, Takada A. Impaired fibrinolysis early after percutaneous transluminal coronary angioplasty is associated with restenosis. Am Heart J 1996; 131: 1-6.
13. Ishiwata S, Tukada T, Nakanishi S, Nishiyama S, Seki A. Postangioplasty restenosis. platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. Am Heart J 1997; 133: 387-92.
14. Huber K, Jorg M, Probst P, Schuster E, Lang I, Kaindl F, Binder BR. A decrease in plasminogen activator inhibitor-1 activity after successful percutaneous transluminal coronary angioplasty is associated with a significantly reduced risk for coronary restenosis. Thromb Haemost 1992; 67: 209-13.
15. Lins M, Zurborn KH, Dau O, Nagel E, Muurling S, Herrmann G, Simon R. Coagulation activation in patients undergoing directional coronary atherectomy. Thromb Res 1997; 86: 433-41.
16. Gottsauner-Wolf M, Sochor H, Hornykewycz S, Beckmann R, Lang I, Probst P, Binder BR, Huber K. Predictive value of PAI-1 plasma activity and thallium perfusion imaging for restenosis after percutaneous transluminal angioplasty in clinically asymptomatic patients. Thromb Haemost 1999; 81: 522-6.
17. Strauss BHLH, Bowman KA, Sparkes J, Chisholm RJ, Garvey MB, Fenkell LL, Natarajan MK, Singh I, Teitel JM. Plasma urokinase antigen and plasminogen activator inhibitor-1 antigen levels predict angiographic coronary restenosis. Circulation 1999; 100: 1616-22.
18. Tohgi H, Takahashi H, Chiba K, Tamura K. Coagulation-fibrinolysis system in poststroke patients receiving antiplatelet medication. Stroke 1993; 24: 801-4.
19. Schomig A, Neumann FJ, Kastrati A, Schuhlen H, Blasini R, Hadamitzky M, Walter H, Zitzmann-Roth EM, Richardt G, Alt E, Schmitt C, Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334: 1084-9.
20. Berg JMt, Kelder JC, Suttorp MJ, Mast EG, Bal E, Ernst SMPG, Verheugt FWA, Plokker HWT. Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial. Circulation 2000; 102: 386-91.
21. Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol 2003; 41 (Suppl. 1): S62-S69.
22. Gottsauner-Wolf M, Zasmeta G, Hornykewycz S, Nikfardjam M, Stepan E, Wexberg P, Zorn G, Glogar D, Probst P, Maurer G, Huber K. Plasma levels of C-reactive protein after coronary stent implantation. Eur Heart J 2000; 21: 1152-8.
23. Carroll VA, Griffiths MR, Geiger M, Merlo C, Furlan M, Lammle B, Binder BR. Plasma protein C inhibitor is elevated in survivors of myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17: 114-8.
24. Carmeliet P, Collen D. Gene targeting and gene transfer studies of the biological role of the plasminogen/plasmin system. Thromb Haemost 1995; 74: 429-36.
25. Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
26. Diamantopoulos L, Huang Y, Liu X, Li S, Desmet W, Van De Werf F, De Scheerder I. Arterial wall temperature following coronary stent implantation in pigs: the role of post-stent inflammation. J Invas Cardiol 2003; 15: 191-7.
27. Loskutoff DJ. PAI-1 inhibits neointimal formation after arterial injury in mice: a new target for controlling restenosis? Circulation 1997; 96: 2772-4.
28. Luttun A, Lupu F, Storkebaum E, Hoylaerts MF, Moons L, Crawley J, Bono F, Poole AR, Tipping P, Herbert JM, Collen D, Carmeliet P. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler Thromb Vasc Biol 2002; 22: 499-505.